# A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)

> **NCT05526521** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 15 (actual)

## Conditions studied

- Chronic Spontaneous Urticaria

## Interventions

- **DRUG:** Dupilumab

## Key facts

- **NCT ID:** NCT05526521
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-25
- **Primary completion:** 2024-11-11
- **Final completion:** 2025-02-03
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05526521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05526521, "A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05526521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*